Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
We are proud to be a key supporter and member of the newly formed BioHive, a collective representing the life science and healthcare innovation ecosystem. By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America. And our innovations are improving
IONIQ Sciences has been recognized by Global 100 as having 2020’s “Most Innovative Non-Invasive Lung Cancer Testing Solution.” This year has seen our IONIQ ProLung Test™ receive widespread recognition for its life-saving potential, including a “Breakthrough Device” designation from the FDA. Global 100 is the
IONIQ Sciences is featured in Healthcare Sales & Marketing’s (HS&M) recent issue as an “innovator at the forefront.” HS&M is dedicated to sales and marketing healthcare professionals across all sectors and they highlight major movers in the industry, spotlight cutting-edge companies, and feature visionary thinking and acting. We appear in an
